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Aberrant CpG island (CGI) methylation occurs early in colorectal neoplasia. Quantitative methylation-specific PCR profiling applied
to biopsies was used to quantify low levels of CGI methylation of 18 genes in the morphologically normal colonic mucosa of
neoplasia-free subjects, adenomatous polyp patients, cancer patients and their tumours. Multivariate statistical analyses distinguished
tumour from mucosa with a sensitivity of 78.9% and a specificity of 100% (P¼3 10
 7). In morphologically normal mucosa, age-
dependent CGI methylation was observed for APC, AXIN2, DKK1, HPP1, N33, p16, SFRP1, SFRP2 and SFRP4 genes, and significant
differences in CGI methylation levels were detected between groups. Multinomial logistic regression models based on the CGI
methylation profiles from normal mucosa correctly identified 78.9% of cancer patients and 87.9% of non-cancer (neoplasia-
freeþpolyp) patients (P¼4.93 10
 7) using APC, HPP1, p16, SFRP4, WIF1 and ESR1 methylation as the most informative variables.
Similarly, CGI methylation of SFRP4, SFRP5 and WIF1 correctly identified 61.5% of polyp patients and 78.9% of neoplasia-free subjects
(P¼0.0167). The apparently normal mucosal field of patients presenting with neoplasia has evidently undergone significant epigenetic
modification. Methylation of the genes selected by the models may play a role in the earliest stages of the development of colorectal
neoplasia.
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Colorectal cancer is believed to develop primarily via the relatively
well-characterised adenoma–carcinoma sequence (Lynch and
Hoops, 2002). Although there is much variability in the overall
profile of genetic abnormalities in any particular tumour (Jass,
2004), the transformation from normal mucosa to carcinoma is
driven by the acquisition of mutations affecting genes involved in
the control of cell proliferation, apoptosis and DNA repair. It is
increasingly recognised that epigenetic changes, in which tran-
scriptional silencing occurs independently of any change in DNA
sequence, also play an important role. The most widely studied
epigenetic event in colorectal carcinogenesis is the hypermethyla-
tion of CpG islands (CGI) associated with the promoter and first
exon regions of tumour-suppressor genes (Esteller, 2003). A
substantial minority of sporadic cancers have a very high level of
CGI methylation affecting many genes; these are referred to as
having the CGI methylator phenotype (CIMP), which appears to
develop through a distinct pathway, having its origin in
hyperplastic polyps rather than in adenomas (Issa, 2004). Hitherto,
there has been a focus on the biology of the primary tumour
and its immediate non-malignant precursor lesions rather than on
the apparently normal epithelial cells in which the carcinogenic
sequence begins. Nevertheless, there is a growing realisation
that the emergence of focal lesions occurs in association with
field changes, which can be defined as abnormalities of epithelial
gene expression affecting the mucosal surface, rendering it
vulnerable to neoplasia. This phenomenon of field cancerisation
was first demonstrated in oral mucosa, in cases of multiple
primary tumours or locally recurrent cancer (Slaughter et al,
1953), where it was believed to extend only a few centimetres
beyond the tumour margin. However, more recent studies
suggest that certain field abnormalities of the colon extend much
further, perhaps encompassing the entire mucosal field (Polley
et al, 2006).
Epigenetic modifications, in particular age-related CGI methyla-
tion, have been suggested to contribute to the field defect in the
colon (Issa et al, 1994; Shen et al, 2005). Because aberrant CGI
methylation occurs early, and is functionally linked with
carcinogenesis, it offers the potential to provide biomarkers to
assess an individual’s risk of having or developing neoplasia. We
have explored these issues using a quantitative methylation-
specific PCR (QMSP) assay approach to measure the methylation
status of 18 genes, previously demonstrated to play a role in
colorectal carcinogenesis, and/or be affected by aberrant CGI
methylation-induced gene silencing, in the morphologically
normal mucosa of patients free from neoplasia at endoscopy, in
adenomatous polyp patients and in both morphologically normal
mucosa and tumour tissue from colorectal cancer patients. Using
multivariate statistics applied to the often subtle differences in
observed methylation status, we show that the apparently normal
mucosa of cancer patients, and to a lesser extent of polyp patients,
has undergone epigenetic modifications that distinguish them
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sfrom patients free of neoplasia, and we identify a set of CGIs that
contribute significantly to this field defect.
MATERIALS AND METHODS
Patients and biopsies
All volunteers were recruited from the gastroenterology outpatient
and surgical lists of the Wansbeck General Hospital (Ashington,
Northumberland, UK). Volunteers were either patients with
previously diagnosed colorectal cancer or adenomatous polyps,
or outpatients with no known gastrointestinal pathology who were
undergoing flexible sigmoidoscopy or colonoscopy as a diagnostic
procedure, typically for the investigation of nonspecific symptoms,
such as abnormal bowel habit or unexplained rectal bleeding.
Ethical approval for the project was received from the North-
umberland Local Research Ethics Committee (Project reference
NLREC2/2001) and consent was obtained in advance of the
expected date of endoscopy or surgery. Experimental biopsies were
collected from the sigmoid colon or rectum of the endoscopy
patients and, for the cancer patients, samples of both normal
mucosa (410cm from tumour margin) and tumour tissue were
collected in operation theatre, immediately after surgery. All
samples were immediately snap-frozen in liquid nitrogen and
transferred to a  801C freezer. Medical notes and pathology
reports for each volunteer were reviewed 6–8 weeks after the
procedure.
Samples of mucosa and tumour tissue were obtained from a
total of 19 patients undergoing surgery for colorectal cancer (11
males and 8 females) with a median age of 74 years (range 52–86
years). Thirteen adenomatous polyp patients were recruited (10
males and 3 females) with a median age of 67 years (range 47–76
years). The ‘healthy’ group comprised 10 males and 10 females,
median age 55 years (range 24–82 years), examined by flexible
sigmoidoscopy (13 patients) or colonoscopy (7 patients), all of
whom were diagnosed as being free from inflammatory bowel
disease, hyperplastic polyps, adenomatous polyps and colorectal
cancer.
Bisulphite conversion of genomic DNA and analysis of CGI
methylation
Biopsies were thawed, and genomic DNA was extracted and
purified using a Genelute DNA extraction kit (Sigma-Aldrich,
Gillingham, UK). Bisulphite conversion of DNA was carried out
according to the method of Raizis et al (1995), which results in
499.8% conversion of unmethylated cytosines to uracil (Belshaw
et al, 2004). CpG island methylation analysis was carried out on all
the tissue samples for 18 genes, selected for their potential
involvement in colorectal neoplasia and previously demonstrated
to be affected by aberrant CGI methylation in colorectal cancer,
using a QMSP assay developed in this laboratory. The selected
genes were as follows: SFRP1, SFRP2, SFRP4, SFRP5 (secreted
frizzled-related proteins), AXIN2 (Axis inhibition protein 2), WIF1
(WNT inhibitory factor 1), APC (Adenomatous Polyposis Coli),
CDH1 (E-cadherin), HPP1/TMEFF2 (Hyperplastic polyposis
protein 1/Transmembrane protein with EGF-like and two follista-
tin-like domains 2), ESR1 (Oestrogen receptor a), MGMT
(O
6-methylguanine-DNA methyltransferase), MLH1 (MutL homo-
logue), p14
ARF, p16
INK4a, MYOD1 (Myogenic differentiation 1), N33
(putative oligosaccharyl transferase), DKK1 (Dickkopf-1) and
MINT31 (CGI 2kb upstream of CACNA1G, a T-type calcium
channel gene).
After bisulphite conversion, each CGI was amplified using
primers not containing CpGs to give a pool of PCR fragments, each
with a C or T at each CpG within the island. The proportion of PCR
fragments containing C at each CpG, and therefore methylated in
the genomic DNA, was determined using real-time PCR (MSP-M)
with SYBR green as reporter, and primers containing Cs at the CpG
sites, designed specifically to amplify the originally methylated
alleles. By comparing the amplification threshold for the sample
DNA with that obtained for a standard from a cloned PCR
fragment derived from bisulphite-modified DNA that had been
fully methylated by the treatment with SssI methylase, the relative
number of copies of methylated fragments was determined. The
total number of PCR fragments present in the amplified pool was
then determined from a second real-time PCR (MSP-T) with
primers not containing CpGs, and the methylation status of the
CGI was calculated. No-template, unmethylated and methylated
controls were included in each assay.
Each CGI was first amplified by PCR in a reaction containing
50ng bisulphite-modified DNA, 4pmol of the appropriate primer
(Supplementary Table S1), 10ml HotstarTaq master mix (Qiagen,
Crawley, UK), 0.5mM MgCl2 and water to 20ml. Following a 15-min
hot start at 951C, the PCR was performed using 35 cycles of
denaturing at 951C for 30s, annealing for 1min and extension at
721C for 1min. The T and M reactions were performed using
4pmol of the appropriate primers (Supplementary Table S1), on
5ml of the amplified CGI fragment diluted 0.1–2.5 10
5 times, in
triplicate PCRs containing 10ml Immomix (Bioline, London, UK),
BSA (1mgml
 1), 0.5mM MgCl2, 0.125ml 100  SYBR green
(Invitrogen, Paisley, UK), 0.4ml ROX reference dye (Invitrogen)
and water to 20ml. Following a 7-min hot start at 951C, PCRs were
performed for 40 cycles of denaturing at 951C for 30s, annealing
for 30s and extension at 721C for 30s using an ABI 7300 machine
(Applied Biosystems, Warrington, UK). A serial dilution (0.5–
50pg) of plasmid containing an insert amplified from fully
methylated DNA was included on each plate as a standard. The
level of allele-specific methylation was determined from standard
curves, plotting Ct vs copy number for the T and M reactions for
the serial-diluted plasmids. Percentage of methylation was
calculated by dividing the number of methylated copies by the
total number of copies. Samples were selected at random following
T and M reactions and subjected to agarose gel electrophoresis to
confirm PCR specificity and to check for primer–dimer formation.
Preparation of plasmid standards for the QMSP assay
Placental DNA (Sigma-Aldrich) was artificially methylated with
SssI (CpG) methylase (New England Biolabs, Hitchin, UK) and
S-adenosylmethionine according to the enzyme manufacturer’s
instructions. Following bisulphite modification, each CGI was
PCR-amplified, using primers listed in Table S1 as described
above. The amplified CGI fragments were gel-purified using a
QIAquick gel extraction kit (Qiagen) according to the manufac-
turer’s instructions, inserted into pCR4-TOPO TA cloning vector
(Invitrogen) and used to transform Escherichia coli TOP10-
competent cells (Invitrogen). Clones were re-suspended in 50ml
water and screened using MSP-M PCRs as described above.
Plasmid DNA was purified from positive clones using a QIAprep
spin miniprep kit (Qiagen) and the inserts were sequenced using a
BigDye terminator cycle sequencing kit and an ABI 3100 Avant
sequencer (Applied Biosystems). Plasmids containing inserts with
a C at each CpG were used as standards in the QMSP assays.
Statistical analysis
Mean and median methylation levels for sample groups were
compared by one-way ANOVA, followed by Tukey’s test for the
significance of differences. Where there was evidence of non-
normality in the response variable, it was transformed to fit a
normal distribution.
To search for differences in patterns of CGI methylation among
the patient groups, we used binomial or multinomial logistic
regression models fitted by regressing the tissue sample types on a
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snumber of genes as well as on age and sex. These variables were
then ‘pruned’ using both backwards elimination using ANOVA-
type tests, and an automated stepwise procedure for optimising the
Akaike Information Criterion (AIC). ‘Leave-one-out’ cross-valida-
tion was used to estimate the classification error rate. This was
compared with the expected rate given by the proportional chance
criterion using an exact binomial test (one-sided) to test the null
hypothesis that the given success rate of classification was no
better than chance. Statistical analyses were carried out using
Minitab Release 14 (Minitab Inc., State College, PA, USA) or ‘R’
(R Core Development team, http://www.R-project.org).
RESULTS
Validity and sensitivity of the QMSP assays
The validity of the QMSP assay for each of the 18 CGIs was
confirmed using a dilution series of artificially methylated DNA in
unmethylated DNA (Supplementary Figure S1). For each assay, a
linear decrease in the measured level of CGI methylation with
dilution of the methylated DNA with unmethylated DNA was
observed, indicating that the assay provides accurate determina-
tion of CGI methylation over several orders of magnitude, and also
demonstrating an absence of any bias of unmethylated over
methylated alleles introduced by PCR amplification (Warnecke
et al, 1997). To illustrate the reproducibility of the QMSP assay, 10
independent assays for the MLH1 CGI were performed on
bisulphite-modified DNA from the cell lines HT-29 and SW48.
The mean (±s.e.m.) levels of methylation measured were
3.57±0.31 and 99.6±1.6%, respectively.
CGI methylation in matched apparently normal and
tumour tissue
A comparison of the median levels of methylation in DNA from
tumour tissue and paired apparently normal mucosa for 18 genes
is presented in Table 1. For 13 genes, the levels of methylation in
the tumour tissue exceeded those of the flat mucosa in the same
patients, and for 7 genes these differences were statistically
significant (Po0.05). For only one gene (AXIN2), the level of
methylation was significantly lower in tumour tissue compared
with flat mucosa (Po0.001).
We used binomial logistic regression modelling to compare the
patterns of CGI methylation in the matched apparently normal and
tumour tissues. Use of backwards elimination selected CGI
methylation of SFRP1, SFRP2, MYOD and MINT31 as the most
informative variables . The model correctly classified 34 out of 38
(89.5%) samples giving a sensitivity for tumour classification of
78.9% with a specificity of 100%. The ‘proportional chance
criterion’ predicts correct classification of 50% of the samples by
chance alone; therefore, an exact one-sided test of 34 out of 38
samples correctly classified resulted in a P-value of 3 10
 7. Thus,
excellent discrimination between tumour tissue and normal
mucosa from the same subjects was achieved by multivariate
analysis of their patterns of CGI methylation, with a very high level
of statistical significance.
CGI methylation in the normal mucosa from
neoplasia-free, adenomatous polyp and cancer patients
We compared the levels of CGI methylation for all 18 genes in the
morphologically normal mucosa of patients with no detectable
neoplasia, in polyp patients and in the cancer patients (Table 2).
Some degree of methylation was detectable in the mucosa of
neoplasia-free patients for all the genes assayed, although the levels
varied considerably for different genes, from approximately 0.1%
for DKK1 to approximately 20% in the case of N33. For APC and
p16, we observed significantly higher levels of methylation in
cancer patients compared with neoplasia-free patients, with
intermediate levels in the adenoma patients after adjusting for
age and gender. The level of methylation was significantly lower in
normal-appearing cancer mucosa compared with neoplasia-free
mucosa for ESR1, MINT31 and WIF1 (Table 2).
Regression analyses revealed statistically significant positive
correlations between CGI methylation and age of all subjects for
APC (R¼0.331, P¼0.015), AXIN2 (R¼0.334, P¼0.014), DKK1
(R¼0.341, P¼0.012), HPP1 (R¼0.484, Po0.001), N33 (R¼0.356,
P¼0.008), p16 (R¼0.355, P¼0.008), SFRP1 (R¼0.532, Po0.001),
SFRP2 (R¼0.345, P¼0.011) and SFRP4 (R¼0.325, P¼0.018).
Stratifying the data by patient group led to a loss of statistical
significance for some of the genes, but this is probably due to the
small number of samples per group. Analysis of variance showed
males were significantly (Po0.05) associated with higher methyla-
tion levels for WIF1, SFRP1 and MGMT (Figure 1). Adjusting the
data for age and patient group led to a loss of statistical
significance for MGMT. The positive association of males
with the methylation of WIF1 and SFRP1 remained
statistically significant (Po0.01) but only in the neoplasia-free
group.
We used multinomial modelling techniques to compare CGI
methylation profiles in apparently normal mucosa samples from
the cancer vs adenomatous polyp and vs neoplasia-free patients.
The logistic regression model using automated backwards
elimination with optimised AIC correctly classified 35 out of 52
(67.3%) of the samples with 16 out of 19 (84.2%, P¼1.15 10
 5)
cancers, 5 out of 13 (38.5%, P¼0.48) polyps and 14 out of 20 (70%,
P¼0.00125) neoplasia-free patients correctly identified. The
variables selected as the most informative were CGI methylation
of HPP1, APC, SFRP4, p16, ESR1 and WIF1. Re-analysing the data
with this model and grouping the neoplasia-free and polyp patients
together as non-cancer subjects led to the correct classification of
29 out of 33 (87.9%, P¼2.94 10
 10) individuals. Thus, successful
discrimination was achieved between the morphologically normal
mucosa of cancer patients and those without cancer with a high
level of statistical significance. However, this model was unable to
distinguish the apparently normal mucosa of patients with
Table 1 CGI methylation in 18 genes associated with colorectal
carcinogenesis in the normal mucosa and tumours of cancer patients
Normal mucosa
a Tumour
CGI methylation (%)
Median (range)
CGI methylation (%)
Median (range) P-value
b
APC 1.24 (0.2–4.8) 2.59 (0.1–43.5) 0.137
AXIN2 2.68 (1.3–5.8) 0.91 (0.3–6.7) 4.72 10
 6
CDH1 3.96 (0.3–9.9) 3.93 (0.2–14.2) 0.904
DKK1 0.21 (0–1.8) 0.21 (0–14.5) 0.637
ESR1 8.64 (4.6–11.5) 13.31 (5.5–28.9) 0.0019
HPP1 1.00 (0.3–2.9) 16.22 (0–43.4) 1.18 10
 11
MGMT 1.21 (0.2–4.2) 2.46 (0.1–11.3) 0.302
MINT31 0.60 (0–4.3) 0.89 (0.2–19.5) 0.259
MLH1 1.01 (0.5–1.3) 0.99 (0.3–16.0) 0.232
MYOD 9.33 (2.5–31.0) 26.17 (4.5–58.7) 0.0002
N33 17.63 (4.0–44.0) 37.89 (11.3–57.8) 0.0040
p14 9.43 (1.6–18.1) 10.92 (0.2–84.0) 0.143
p16 0.33 (0–1.2) 0.52 (0–10.5) 0.284
SFRP1 1.90 (0.5–5.3) 8.86 (2.0–25.6) 1.61 10
 6
SFRP2 2.11 (0.3–8.5) 15.49 (0.4–54.8) 9.74 10
 10
SFRP4 0.96 (0–9.3) 0.94 (0–49.4) 0.987
SFRP5 0.50 (0–0.9) 0.70 (0–46.9) 0.0324
WIF1 1.75 (0.2–23.7) 3.81 (0.3–60.9) 0.300
CGI¼CpG island.
aValues are median levels of methylation and ranges for 19 cancer
patients.
bP-values are for the comparison of mean methylation levels from the
mucosa with those from the tumour using ANOVA following transformation of the
response variable where appropriate.
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logistic regression modelling for polyp patients vs neoplasia-free
subjects correctly classified 8 out of 13 (61.5%) polyp patients and
15 out of 19 (78.9%) neoplasia-free subjects (P¼0.0167). The
variables selected as the most informative were CGI methylation of
SFRP4, SFRP5 and WIF1. Thus, discrimination between mucosal
samples from neoplasia-free subjects and those with adenomatous
polyps was relatively low, compared with the discrimination
achieved between the morphologically normal mucosa of cancer
patients and those without cancer, although still statistically
significant.
DISCUSSION
A large number of studies have now identified a role for aberrant
CGI methylation in gene silencing during colorectal carcinogen-
esis, with many CGIs reportedly affected in both tumours (Jones
and Baylin, 2002) and in pre-cancerous lesions (Chan and Rashid,
2006). More recently, aberrant CGI methylation has been
investigated in the normal mucosa of individuals with and without
neoplastic lesions. In a comparison of patients with and without
adenomas, the methylation of p16, MLH1 and MGMT could not
predict the presence of adenoma (Ye et al, 2006); in colorectal
cancer patients, significant methylation was observed at the
surgical margin (p10cm from tumour) and was shown to be
influenced by gender and by a polymorphism in the DNMT3B gene
(Shen et al, 2005; Kawakami et al, 2006; Zhang et al, 2006;
Iacopetta et al, 2007). Other studies have examined hyperplastic
polyposis, where extensive methylation may underlie the condition
(Minoo et al, 2006), and neoplasia-free, adenoma, hyperplastic
polyp and cancer patients, where ESR1 and MLH1 methylation
were generally higher in subjects with neoplasia, and were
negatively associated with vitamin B-12 status (Al-Ghnaniem
et al, 2007). In the present study, we have extended the
investigation of methylation events in the mucosal field by using
a QMSP assay to measure CGI methylation in 18 genes selected
from the literature for their involvement in colorectal neoplasia,
and shown previously to be affected by aberrant CGI methylation.
Our findings suggest that changes in the methylation status of
certain CGIs may contribute to, and therefore be used to define,
the field defect associated with the development of colorectal
neoplasia.
The QMSP method used here enabled us to measure accurately
the often low levels of methylation for each CGI as a continuous
variable. Using these data, we then applied multivariate statistical
analyses to test the hypothesis that CGI methylation patterns in the
morphologically normal mucosa of both cancer and adenomatous
polyp patients differed significantly from those of patients with no
neoplasia. The highly significant differences observed clearly
demonstrate that the apparently normal mucosa of patients
presenting with tumours or polyps has undergone epigenetic
changes associated with the emergence of focal lesions elsewhere in
the mucosal field. It should be noted that not all neoplasia-free
patients underwent a full colonoscopy. However, 13 patients
examined by flexible sigmoidoscopy were regarded as being at low
risk of proximal lesions, and were discharged by the clinicians as
free of neoplasia and inflammatory bowel disease. Although there
is still a small risk that some patients harboured undiagnosed
lesions in the proximal colon, this would presumably have tended
to reduce the detected differences between groups.
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Figure 1 Differences in mean CGI methylation levels (±s.e.m.) in the
apparently normal mucosa of males and females for MGMT (P¼0.003),
SFRP1 (P¼0.003) and WIF1 (P¼0.005). P-values were determined by
ANOVA.
Table 2 CGI methylation in 18 genes associated with colorectal carcinogenesis in the normal mucosa of neoplasia-free, polyp and cancer patients
Neoplasia-free
a (n¼20) Polyp (n¼13) Cancer (n¼19)
CGI methylation (%)
Median (range)
CGI methylation (%)
Median (range)
CGI methylation (%)
Median (range) P-value
b
APC 0.40 (0.1–1.4) 0.55 (0–1.4) 1.24 (0.2–4.8) 0.013
AXIN2 2.10 (1.1–3.6) 1.95 (0.6–3.4) 2.68 (1.3–5.8) 0.556
CDH1 3.64 (0.2–9.6) 5.41 (1.3–8.5) 3.96 (0.3–9.9) 0.789
DKK1 0.14 (0–0.9) 0.17 (0–0.7) 0.21 (0–1.8) 0.070
ESR1 10.55 (3.8–16.5) 9.21 (4.4–14.0) 8.64 (4.6–11.5) 0.019
HPP1 0.50 (0–1.7) 0.96 (0–3.1) 1.00 (0.3–2.9) 0.708
MGMT 0.96 (0.3–4.0) 1.59 (0.6–4.8) 1.21 (0.2–4.2) 0.630
MINT31 2.20 (0.2–42.2) 2.22 (0.7–14.8) 0.60 (0–4.3) 0.016
MLH1 0.83 (0.1–2.9) 0.54 (0.2–5.3) 1.01 (0.5–1.3) 0.787
MYOD 11.43 (2.0–92.0) 21.00 (4.2–45.0) 9.33 (2.5–31.0) 0.301
N33 15.6 (5.3–38.4) 15.0 (8.5–27.6) 17.63 (4.0–44.0) 0.671
p14 6.07 (0–24.5) 6.37 (2.7–17.7) 9.43 (1.6–18.1) 0.622
p16 0.21 (0–0.6) 0.20 (0.1–0.6) 0.33 (0–1.2) 0.024
SFRP1 0.89 (0.1–4.1) 1.73 (0.3–3.7) 1.90 (0.5–5.3) 0.663
SFRP2 1.91 (0.2–6.6) 2.62 (1.4–8.5) 2.11 (0.3–8.5) 0.167
SFRP4 0.77 (0.2–3.9) 1.99 (0.5–4.6) 0.96 (0–9.3) 0.511
SFRP5 0.37 (0–2.0) 0.20 (0–1.5) 0.50 (0–0.9) 0.107
WIF1 11.76 (1.7–33.2) 19.18 (11.4–48.8) 1.75 (0.2–23.7) 0.005
CGI¼CpG island.
aValues are median levels of methylation and ranges for mucosa samples from 20 patients free of neoplasia, 13 adenomatous polyp patients and 19 cancer
patients.
bP-values are for the comparison of mean methylation levels from the mucosa of neoplasia-free patients with those from cancer patients using ANOVA. The analysis
was performed after adjusting for age and sex, and following transformation of the response variable where appropriate.
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sThe low levels of CGI methylation in morphologically normal
mucosa have previously been dismissed as biologically insignif-
icant on the grounds that they would have no measurable effect on
gene expression (Ogino et al, 2006a, 2006b). However, QMSP
measures CGI methylation, which probably occurs in an allele-
specific manner (Supplementary Figure S2; Fackler et al, 2004;
Belshaw et al, 2005). Because each colonic crypt is populated by
clonal expansion of stem cells, aberrant CGI methylation is more
likely to occur discretely in individual crypts. Furthermore,
because crypts divide by fission, this mechanism might be
expected to give rise to localised ‘islands’ or patches of
hypermethylation within an otherwise normal (unmethylated)
field (Preston et al, 2003). Thus, low levels of CGI methylation
detected in mucosal biopsies may be of great biological
significance, as they represent the mean of localised methylation
events distributed unevenly within the epithelium. Recent evidence
of MLH1 CGI methylation affecting small patches of crypts in the
unaffected mucosa of colorectal carcinoma patients provides
support for this hypothesis (Nuovo et al, 2006).
Issa et al (1994) were the first to report that ESR1 undergoes age-
dependent methylation in the healthy human colon, and to
propose that this form of epigenetic field effect may contribute
to the increasing risk of colorectal cancer with age. In a subsequent
work (Toyota et al, 1999), this group proposed a distinction
between genes that commonly undergo age-dependent methylation
(Type A) and those that become methylated only during the
development of cancer (Type C). The panel of 18 genes used in the
present study includes examples of both Type C and Type A genes
as described by Issa and colleagues (Toyota et al, 1999). However,
it should be noted that in a recent study, Kawakami et al (2006)
observed age-related increases in CGI methylation for some genes
classified as Type C by Toyota et al, which argues against any such
rigid classification. In the present study, we observed statistically
significant age-related increases in CGI methylation for HPP1, p16,
APC, AXIN2, SFRP1, SFRP2, SFRP4, N33 and DKK1, but contrary
to previous studies (Issa et al, 1994; Kawakami et al, 2006;
Al-Ghnaniem et al, 2007), the CGI methylation of ESR1, MYOD and
MLH1 showed no correlation with age in our patients. These
findings may be due to analytical differences resulting in different
CpGs within each island analysed or may indicate that the rates
and sites of CGI methylation differ between populations, perhaps
because of genotypic variation (Kawakami et al, 2006) or differing
exposure to environmental factors, such as diet (Al-Ghnaniem
et al, 2007) or commensal microorganisms.
Although CGI methylation of several genes was positively
associated with age, age was not selected as a distinguishing
variable by the logistic regression models. Furthermore, seven
genes (MLH1, DKK1, AXIN2, MGMT, N33, p14 and CDH1) were
not selected by any of the models as features distinguishing
between the disease states, indicating that their extent of
methylation made no systematic contribution to the proposed
‘field defect’ in this study.
Higher methylation levels in the normal mucosa were associated
with the male gender for WIF1, SFRP1 and MGMT, which confirms
the nonsignificant indication for male-associated methylation of
MGMT observed by Shen et al (2005), but contradicts a recent
report that the female gender was generally associated with higher
CGI methylation levels in the normal mucosa of cancer patients
(Kawakami et al, 2006). Interestingly, stratifying the data by
patient group and adjusting for age showed that the male-
associated increased methylation of WIF1 and SFRP1 was specific
for the neoplasia-free subjects only.
The genes selected by the logistic regression models, used here
as the most informative for distinguishing between the disease
states, seem more likely to be mechanistically important for
carcinogenesis. The genes distinguishing tumours from matched
normal mucosa were SFRP1, SFRP2, MYOD and MINT31, whereas
those distinguishing the morphologically normal mucosa of cancer
patients from that of non-cancer (neoplasia-freeþpolyp) patients
were HPP1, APC, p16, SFRP4, ESR1 and WIF1, although SFRP4,
SFRP5 and WIF1 could distinguish the normal mucosa of polyp
patients from those without neoplasia. The observed CGI
methylation of HPP1 in this context is potentially of great interest.
The methylation of HPP1 was identified originally in hyperplastic
polyps (hence the name), but it was also detected in colonic
cancers, adenomas and in the normal mucosa, particularly of
individuals bearing cancers with microsatellite instability (Young
et al, 2001). HPP1 methylation has also been detected in the
dysplastic mucosa of ulcerative colitis patients (Sato et al, 2002).
More recently, HPP1 methylation was shown to occur early in
Barrett’s-associated neoplastic progression to oesophageal adeno-
carcinoma, and was predictive of progression risk (Schulmann
et al, 2005).
There is good evidence that the aberrant activation of the Wnt
signalling pathway is causal for approximately 90% of colorectal
cancer (Giles et al, 2003). Previous studies (Suzuki et al, 2004) have
suggested that CGI methylation-induced silencing of Wnt pathway
antagonists may constitute an ‘epigenetic gatekeeper’, leading to
constitutive activation of the Wnt pathway, and perhaps to
‘addiction’ in specific epithelial cells to its overactivity (Baylin
and Ohm, 2006). This may favour the acquisition of mutations in
downstream factors, eventually facilitating tumour progression. In
the present study, the identification of CGI methylation of the Wnt
signalling pathway regulatory genes APC, SFRP1, SFRP2, SFRP4,
SFRP5 and WIF1 as significant features contributing to the
discrimination of tumours from normal mucosa, cancer mucosa
from non-cancer mucosa and polyp mucosa from neoplasia-free
mucosa is consistent with this hypothesis. Coupled with the
significant age-dependence of CGI methylation for six out of the
eight Wnt antagonist genes studied here, these observations
highlight the potential importance of these methylation events in
the formation of the field defect.
CpG island methylation of both WIF1 and ESR1 genes made a
significant contribution to the distinction between the normal
mucosa of cancer patients and that of neoplasia-free patients.
However, the average methylation levels were significantly higher
in neoplasia-free subjects compared with cancer patients (Table 2)
This observation suggests that epigenetic field changes may
include both loss and gain of methylation. Our data for ESR1
contradict those of Al-Ghnaniem et al (2007) who reported that
ESR1 was 19% more methylated in the normal mucosa of cancer
patients than in those free of disease. The role of WIF1 in the
Wnt signalling pathway is poorly understood. WIF1 binds to
secreted Wnt ligands (Hsieh et al, 1999) and is frequently
downregulated by CGI methylation in gastrointestinal cancers,
including colorectal adenomas (Taniguchi et al, 2005). Recently,
WIF1 expression was observed throughout normal colonic crypts
with enhanced expression in the stem cell zone at the crypt base
(Byun et al, 2005). However, another study found that the WIF1
expression was unique to adenomas (Gregorieff et al, 2005).
Furthermore, the WIF1 expression was elevated in intestinal
adenomas compared with the normal epithelia of Apc
Min/þ mice,
and was observed in two human colon adenocarcinoma cell lines
(Cebrat et al, 2004). This led the authors to propose a role for WIF1
in facilitating adenoma growth, perhaps by inhibiting the
generation and/or maintenance of the normal epithelial stem cell
compartment.
As expected, the majority (13 out of 18) of CGIs were more
methylated in tumours than in the matched apparently normal
mucosa, with the difference being statistically significant for seven
CGIs. Interestingly, on average, the AXIN2 CGI was significantly
less methylated in tumours compared with the matched apparently
normal mucosa, and in only one tumour, it was more methylated
than in matched apparently normal mucosa from the same person
(6.8 vs 3.5%). AXIN2 methylation has been reported by others to be
correlated with microsatellite instability (Koinuma et al, 2006).
CpG island methylation in normal colonic mucosa
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(Weisenberger et al, 2006), and CIMP
þ tumours have been
reported to be associated with high CGI methylation levels in the
normal mucosa (Kawakami et al, 2006). The analysis of mean Z-
scores for the CGIs used previously to define CIMP status (MLH1,
MGMT, MINT31, p14 and p16; Minoo et al, 2006) suggests that
only one of our tumours was CIMP
þ (Supplementary Figure S3).
Interestingly, this tumour also had the highest mean Z-score for all
CGIs, indicating extensive methylation for many of the genes.
However, the CGI methylation profile from the normal mucosa
from this individual was not significantly different from those of
the others (data not shown). In future studies, we intend to
determine the performance of our statistical models with a larger
set of cancer patients, in which CIMP status is defined.
In conclusion, the application of quantitative CGI methylation
profiling, together with multinomial logistic regression modelling,
demonstrates a role for CGI methylation as a feature of a
generalised colorectal mucosal field defect associated with the
presence of a neoplastic lesion. Such methylation events may cause
‘addiction’ of cells to aberrant gene expression and play a causal
role at an early stage in the development of neoplasia (Baylin and
Ohm, 2006). The application of this approach to a much larger
population would almost certainly lead to more refined statistical
models, and would enable the study of environmental factors, and
their interaction with genotype, in the modification of DNA
methylation patterns. Quantitative CGI methylation profiling for
the identification and classification of field defects may also
provide an objective approach to the early detection, or the
assessment of risk, of colorectal cancer.
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